GALECTIN-1 IMMUNOMODULATION AND MYOGENIC IMPROVEMENTS IN MUSCLE DISEASES AND AUTOIMMUNE DISORDERS
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
May 23, 2024
app pub date -
Mar 15, 2022
filing date -
Mar 15, 2021
priority date (Note) -
Published
status (Latency Note)
Importance
Loading Importance Indicators... 
Abstract
A method of treating a disease associated with chronic, NFκB canonical inflammation is disclosed herein. The method includes administering to a patient a suitable amount of a galectin-1 protein or fragment thereof. Treatment with a recombinant galectin-1 reduced inflammation in key inflammatory pathways.
Loading the Abstract Image...
OK
First Claim
Family
Loading Family data...
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully